Transplant Complications Drug Development Pipeline Review 2018 - AbbVie, AbGenomics International, Alexion Pharmaceuticals, AnaptysBio, Angion Biomedica, apceth Biopharma, Aptevo Therapeutics, Astellas Pharma

Transplant Complications Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), liver transplant rejection, kidney transplant rejection and lung transplant rejection and features dormant and discontinued products.

GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment consists of immunosuppressants. There are 125 products in development for GVHD.

FREE| Download Sample Copy at https://www.premiummarketinsights.com/sample/GBI00004570?source=OP_HM

Organ transplantation replaces an injured or diseased organ with a healthy one. Following a transplant, the immune system may consider the transplanted tissue as foreign and work against it. Patients can develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, blocking organ rejection and facilitating a successful transplant. There are 18 products in development for liver transplant rejection, 49 products in development for kidney transplant rejection and 12 products in development for lung transplant rejection.

Molecular targets acted on by products in development for transplantation complications include tyrosine kinases, caspases and chemokine receptors. Companies operating in this pipeline space include Medeor Therapeutics, Amgen and Novartis.

Scope

- Which companies are the most active within each pipeline-
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication-
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies-
- What are the most important R&D milestones and data publications to have happened in this disease area-

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 9
2.1 Transplant Complications Report Coverage 9
2.2 Graft Versus Host Disease (GVHD) - Overview 9
2.3 Liver Transplant Rejection - Overview 9
2.4 Kidney Transplant Rejection - Overview 9
2.5 Lung Transplant Rejection - Overview 9
3 Therapeutics Development 10
3.1 Graft Versus Host Disease (GVHD) 10
3.2 Liver Transplant Rejection 23
3.3 Kidney Transplant Rejection 27
3.4 Lung Transplant Rejection 34
4 Therapeutics Assessment 37
4.1 Graft Versus Host Disease (GVHD) 37
4.2 Liver Transplant Rejection 47
4.3 Kidney Transplant Rejection 53
4.4 Lung Transplant Rejection 60
5 Companies Involved in Therapeutics Development 66
5.1 Graft Versus Host Disease (GVHD) 66
5.2 Liver Transplant Rejection 98
5.3 Kidney Transplant Rejection 100
5.4 Lung Transplant Rejection 112
6 Dormant Projects 116
6.1 Graft Versus Host Disease (GVHD) 116
6.2 Liver Transplant Rejection 122
6.3 Kidney Transplant Rejection 123
6.4 Lung Transplant Rejection 126
7 Discontinued Products 127
7.1 Graft Versus Host Disease (GVHD) 127
7.2 Liver Transplant Rejection 128
7.3 Kidney Transplant Rejection 128
8 Product Development Milestones 129
8.1 Graft Versus Host Disease (GVHD) 129
8.2 Liver Transplant Rejection 145
8.3 Kidney Transplant Rejection 148
8.4 Lung Transplant Rejection 162
9 Appendix 172
9.1 Methodology 172
9.2 Coverage 172
9.3 Secondary Research 172
9.4 Primary Research 172
9.5 Expert Panel Validation 172
9.6 Contact Us 172
9.7 Disclaimer 173

Purchase this Premium Research Report at https://www.premiummarketinsights.com/buy/GBI00004570

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.

Pune, India

This release was published on openPR.